New hope for myeloma patients with kidney failure: safer CAR t therapy on the horizon

NCT ID NCT06623630

Recruiting now Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new conditioning regimen (low-dose total body irradiation plus cyclophosphamide) before CAR T therapy (cilta-cel) in 16 multiple myeloma patients with impaired kidney function. The goal is to see if this approach is safe and feasible for patients who are typically excluded from CAR T trials due to kidney issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ciltacabtagene autoleucel (Carvykti) with total body irradiation and cyclophosphamide
What this could lead to: If successful, this could provide a safe way to give CAR T therapy to multiple myeloma patients with kidney problems, who are often excluded from such treatments.
What could go wrong: This is a very early, small Phase 1 trial with only 16 people. The new conditioning regimen may be too toxic or not work as well as the standard approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney failure plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.